Start smarter cancer care with Herceptin Trastuzumab In Turkey
Herceptin (trastuzumab) is a cornerstone of modern targeted cancer therapy, designed to treat tumors driven by overexpression of the HER2 protein. Rather than affecting healthy cells indiscriminately, this treatment focuses on specific biological pathways involved in cancer growth.
At Biruni Hospital, Herceptin is used within a structured, evidence-based treatment plan, ensuring that each patient receives therapy aligned with their diagnosis, disease stage, and overall health profile. While Turkey offers access to this medication, the priority remains careful monitoring, appropriate dosing, and measurable clinical outcomes tailored to each patient.
What is Herceptin (trastuzumab)?
Herceptin, also called trastuzumab, is a smart drug used to treat cancers that overproduce the HER2 protein. This protein helps cancer cells grow faster than normal.
Herceptin attaches to HER2 receptors to block those signals and slow cancer growth. It also helps the immune system target those cells more effectively.
Key aspects of Herceptin trastuzumab treatment
used only for HER2-positive cancers
blocks growth signals in cancer cells
given by intravenous infusion
often combined with other treatments
helps reduce the risk of recurrence
requires heart monitoring throughout treatment
What are the types of cancer that Herceptin (trastuzumab) is used for?
HER2 Positive Breast Cancer
Herceptin is most known for tackling HER2-positive breast cancer. This type tends to grow and spread faster because it has an excess of the HER2 protein.
Herceptin steps in by blocking the signals from this protein, slowing down the cancer’s growth, and giving other treatments a better chance.
It’s usually given after surgery with chemotherapy to reduce the chance of the cancer coming back.
Key aspects of HER2-positive breast cancer treatment
primarily used for this aggressive breast cancer
blocks growth signals from HER2 protein
often combined with chemotherapy
helps improve survival rates
commonly part of long-term therapy
HER2-positive gastric cancer
Though less common, some stomach cancers also show high HER2 levels. Herceptin targets these tumors, slowing their progression.
When paired with chemotherapy, it can help patients live longer and better manage their disease.
It’s typically reserved for advanced or metastatic cases where controlling growth is critical.
Key aspects of HER2-positive gastric cancer treatment
targets HER2-overexpressing stomach tumors
used alongside chemotherapy
aimed at advanced or metastatic cancer
slows down tumor progression
requires HER2 testing beforehand
Metastatic breast cancer
When breast cancer spreads beyond the breast, trastuzumab plays a role in slowing tumor growth and managing symptoms.
The goal here is not cure but control, helping patients maintain quality of life.
It’s commonly used with other therapies and requires regular check-ups to adjust treatment.
Key aspects of metastatic breast cancer treatment
treats cancer that has spread
often combined with chemo or hormone therapy
focuses on controlling progression
aims to improve patient comfort and lifespan
needs ongoing monitoring
Early-stage breast cancer
For early-stage HER2-positive breast cancer, Herceptin is given after surgery to prevent the cancer from returning. Its targeted action helps clean up any leftover cancer cells.
Treatment usually lasts about a year and is part of a carefully planned approach to reduce recurrence risk.
Key aspects of early-stage breast cancer treatment
given post surgery
targets remaining cancer cells
lowers risk of recurrence
typically combined with chemotherapy
administered over several months
What are the types of trastuzumab?
Kanjinti
Kanjinti is basically a copy of Herceptin made by a different company. It works exactly the same way and is just as safe and effective.
The big difference is it usually costs less, which makes this life-saving treatment available to more people.
It’s used in the same way with the same kind of monitoring and schedule. Patients get all the benefits of trastuzumab without paying more than they need to.
How Kanjinti treatment goes
Confirm that the cancer is HER2 positive
Get heart health checked before starting
IV infusions given every one to three weeks
Watch closely for any infusion reactions, especially early on
Usually combined with chemotherapy or hormone treatments
Treatment length depends on how the patient responds and cancer stage
Heart function is monitored regularly throughout treatment
Frequent checkups to make sure the treatment is working and side effects are managed
Ogivri
Ogivri is another biosimilar trastuzumab proven to be just as effective as Herceptin.
It blocks HER2 proteins on cancer cells to slow growth and boost the immune system’s attack.
Like other biosimilars, Ogivri gives patients more options, especially if cost or availability is a concern.
It’s given intravenously on the same schedule and needs the same kind of heart monitoring and follow-up care.
What to expect with Ogivri
Confirm HER2-positive cancer diagnosis before starting
Heart function tested before treatment begins
IV infusions every one to three weeks
Careful observation during initial doses for any reactions
Often used with chemotherapy or hormone therapy
Treatment duration varies depending on patient and disease specifics
Ongoing heart monitoring is essential
Regular follow-ups to check progress and manage side effects
Ontruzant
Ontruzant is the newest trastuzumab biosimilar; it provides the same HER2-targeting action as Herceptin but at a price that can make it easier to access for many patients.
It blocks the HER2 protein and helps the immune system attack cancer cells.
Treatment is intravenous every one to three weeks and includes regular heart function checks and clinical monitoring.
How Ontruzant treatment is delivered
Mandatory HER2 testing before treatment begins
Cardiac assessments before and during treatment
IV infusions every one to three weeks
Close monitoring for infusion reactions especially early on
Usually given with chemotherapy
Treatment length depends on individual patient needs
Heart monitoring throughout therapy
Regular clinical visits to track effectiveness and side effects
What are the common side effects of herceptin ?
Heart concerns
One of the biggest things doctors watch for during treatment is how the drug affects the heart.
Trastuzumab can sometimes weaken the heart muscle, which might lead to feeling more tired or short of breath.
That’s why heart function tests happen regularly before and during treatment, to catch any issues early and keep patients safe.
Infusion reactions
Some patients might feel uncomfortable during or right after the infusion; symptoms like chills, fever, or nausea can pop up, but they’re usually manageable.
The medical team is there to slow the infusion or give medicine so these reactions don’t become a problem.
Fatigue
Feeling wiped out is very common when going through treatment; the body is busy fighting cancer and adjusting to the medication.
This kind of tiredness can last a while, but pacing yourself and taking breaks helps most people cope.
Upset stomach
Nausea, vomiting, or diarrhea can happen to some people; these symptoms vary in how strong they are but can often be eased with the right medications and eating small, frequent meals.
Drinking plenty of fluids is key, and letting your care team know is important.
Breathing issues
It’s rare, but sometimes trastuzumab can cause coughing or trouble breathing.
If this happens, it’s important to tell your doctor right away; early attention prevents bigger problems and keeps treatment on track.
Finding the right path forward
Choosing the right HER2-targeted treatment is about balancing effectiveness, safety, and access. The variety of trastuzumab options today means more patients can receive proven care tailored to their needs.
Careful monitoring and personalized support make all the difference in managing side effects and maximizing benefits.
At Biruni Hospital, patients get expert guidance every step of the way toward better outcomes.